REG - BiVictriX Therapcts. - Appointment of Joint Broker

Bivictrix TherapeuticsAnnouncement

01/11/2021 07:05

RNS Number : 8167Q
  
BiVictriX Therapeutics PLC
  
01 November 2021
  
 

 
BIVICTRIX THERAPEUTICS PLC
("BiVictriX" or "the Company")
 
Appointment of Joint Broker
 
Alderley Park, 1 November 2021  BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, today announces that it has appointed Panmure Gordon (UK) Limited to act as Joint Broker to the Company alongside SP Angel Corporate Finance LLP with immediate effect.
 



  For more information, please contact:
 



BiVictriX Therapeutics plc


 




Tiffany Thorn, Chief Executive Officer
Iain Ross, Chairman
 
 


 
Email: info@bivictrix.com




 


 




SP Angel Corporate Finance LLP (NOMAD and Broker)


Tel: +44 (0) 20 3470 0470


 




David Hignell, Caroline Rowe (Corporate Finance)
Vadim Alexandre, Rob Rees (Sales and Broking)


 


 




 
Panmure Gordon (UK) Limited (Joint Broker)


 
Tel: +44 (0) 20 7886 2500


 




Rupert Dearden/Freddy Crossley/Emma Earl
 
Consilium Strategic Communications


 




Ashley Tapp, Suki Virji, Priit Piip


Tel: +44 (0) 20 3709 5700
Email: Bivictrix@consilium-comms.com




 


 











 
About BiVictriX Therapeutics plc
BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst eliminating treatment-related toxicities.
 
The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni® therapeutics which are designed to selectively target antigen co-expression fingerprints, or "twin antigens", on tumour cells, which are largely absent from healthy cells. Whereas this concept has been validated in a clinical diagnostic setting to support the diagnosis and monitoring of haematological cancers, it has not yet been widely used in a therapeutic setting.
 
BiVictriX has identified a diverse panel of novel cancer-specific "twin antigens", across a broad range of cancer indications including Diffuse Large B Cell Lymphoma, Acute Myeloid Leukaemia and Blastic Plasmacytoid Dendritic Cell Neoplasm. The Company is using these novel "twin-antigens" to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and currently constitute areas of high unmet medical need.
 
Find out more about BiVictriX online at www.bivictrix.com  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
APPDZMFGRMMGMZM